Table 5.
Distribution of iKIRs and their cognate HLA-I ligands in patients and controls.
| Inhibitory KIR/HLA-I ligand | |||
|---|---|---|---|
| AML: n = 181 (%) | Control: n = 181 (%) | P-value OR (95% CI) | |
| KIR2DL1( +)/HLA-C2( +) | 115 (63.5) | 141 (77.9) | 0.002 |
| 0.49 (0.3–0.78) | |||
| KIR2DL1( +)/HLA-C2(–) | 62 (34.3) | 40 (22.1) | 0.01 |
| 1.83 (1.15–2.93) | |||
| KIR2DL1(–)/HLA-C2( +) | 4 (2.2) | 0 | 0.13‡ |
| n = 181 (%) | n = 179 (%) | ||
| KIR2DL2/3( +)/HLA-C1( +) | 118 (65.2) | 134 (74.9) | 0.04 |
| 0.62 (0.39–0.99) | |||
| KIR2DL2/3 ( +)/HLA-C1(–) | 63 (34.8) | 43 (24.0) | 0.02 |
| 1.68 (1.06–2.68) | |||
| KIR2DL2/3(–)/HLA-C1( +) | 0 | 2 (1.1) | 0.47‡ |
| n = 171 (%) | n = 176 (%) | ||
| KIR3DL1( +)/HLA-B Bw4Ile80( +) | 88 (51.5) | 86 (48.9) | 0.62 |
| KIR3DL1( +)/HLA-B Bw4Ile80(–) | 79 (46.2) | 85 (48.3) | 0.69 |
| KIR3DL1(–)/HLA-B Bw4Ile80( +) | 4 (2.3) | 5 (2.8) | 0.96‡ |
| n = 171 (%) | n = 173 (%) | ||
| KIR3DL1( +)/HLA-B Bw4Thr80( +) | 25 (14.6) | 27 (15.6) | 0.79 |
| KIR3DL1( +)/HLA-B Bw4Thr80(–) | 142 (83.0) | 144 (83.2) | 0.96 |
| KIR3DL1(–)/HLA-B Bw4Thr80( +) | 4 (2.3) | 2 (1.2) | 0.67‡ |
| n = 170 (%) | n = 175 (%) | ||
| KIR3DL1( +)/HLA-A Bw4( +) | 47 (27.6) | 66 (37.7) | 0.04 |
| 0.63 (0.4–0.99) | |||
| KIR3DL1( +)/HLA-A Bw4(–) | 120 (70.6) | 105 (60.0) | 0.03 |
| 1.60 (1.02–2.5) | |||
| KIR3DL1(–)/HLA-A Bw4( +) | 3 (1.8) | 4 (2.3) | 0.96‡ |
| n = 175 (%) | n = 179 (%) | ||
| KIR3DL1( +)/HLA Bw4( +) | 126 (72.0) | 128 (71.5) | 0.91 |
| KIR3DL1( +)/HLA Bw4(–) | 41 (23.4) | 43 (24.0) | 0.89 |
| KIR3DL1(–)/HLA Bw4( +) | 8 (4.6) | 8 (4.5) | 0.96 |
| n = 181 (%) | n = 181 (%) | ||
| KIR3DL2( +)/HLA-A*03/11( +) | 59 (32.6) | 79 (43.6) | 0.03 |
| 0.62 (0.4–0.95) | |||
| KIR3DL2( +)/HLA-A*03/11(–) | 122 (67.4) | 102 (56.4) | 1.60 (1.04–2.45) |
The Chi-square test was done based on a 2 × 2 contingency table, p < 0.05 was considered significant. OR: odds ratio, CI: confidence interval.
‡p-value with Yates’ correction.
Significant values are in bold.